Publications by authors named "J Ordi-Ros"
Reduction of disease activity, corticosteroids use, and healthcare resource utilisation in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: OBSErve Spain multicentre study.
Reumatol Clin (Engl Ed)
June 2023
Introduction And Objectives: This OBSErve Spain study, a part of the international OBSErve programme, evaluated belimumab real-world use and effectiveness following 6 months of treatment in patients with active systemic lupus erythematosus (SLE) in clinical practice in Spain.
Materials And Methods: In this retrospective, observational study (GSK Study 200883), eligible patients with SLE receiving intravenous belimumab (10mg/kg) had their disease activity (physician assessed), SELENA-SLEDAI scores, corticosteroid use, and healthcare resource utilisation (HCRU), assessed after 6 months of treatment versus index (belimumab initiation) or 6 months pre-index.
Results: Overall, 64 patients initiated belimumab, mainly due to ineffectiveness of previous treatments (78.
Article Synopsis
- The study aims to assess how thrombocytopenia affects survival rates in patients with Antiphospholipid Syndrome (APS) over a 38-year period.
- Among 114 patients studied, factors like thrombocytopenia, acute arterial events, and myocardial infarctions were linked to mortality risk, with thrombocytopenia showing a strong correlation even after adjusting for other factors.
- The findings suggest that thrombocytopenia indicates a severe disease phenotype in APS patients and is associated with reduced long-term survival, especially when persistent or of low-moderate severity.
Background: Thalidomide has been used successfully in a variety of chronic refractory inflammatory dermatological conditions with underlying autoimmune or infectious pathogenesis. It was first used for refractory discoid lupus erythematosus (DLE) in 1983 and has steadily grown since then.
Method: In this review, we describe the therapeutic benefits of thalidomide for DLE treatment and its biological properties.
Data on exosomal-derived urinary miRNAs have identified several miRNAs associated with disease activity and fibrosis formation, but studies on prognosis are lacking. We conducted a qPCR array screening on urinary exosomes from 14 patients with biopsy-proven proliferative lupus glomerulonephritis with a renal outcome of clinical response ( = 7) and non-response ( = 7) following therapy. Validation studies were performed by qRT-PCR in a new lupus nephritis (LN) cohort (responders = 22 and non-responders = 21).
View Article and Find Full Text PDFBackground: The potential role of new oral anticoagulants in antiphospholipid antibody syndrome (APS) remains uncertain.
Objective: To determine whether rivaroxaban is noninferior to dose-adjusted vitamin K antagonists (VKAs) for thrombotic APS.
Design: 3-year, open-label, randomized noninferiority trial.